Literature DB >> 15522100

Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway.

Ricardo Hermosilla1, Morad Oueslati, Ute Donalies, Eva Schönenberger, Eberhard Krause, Alexander Oksche, Walter Rosenthal, Ralf Schülein.   

Abstract

The G protein-coupled V(2) vasopressin receptor is crucially involved in water reabsorption in the renal collecting duct. Mutations in the human V(2) vasopressin receptor gene cause nephrogenic diabetes insipidus. Many of the disease-causing mutants are retained intracellularly by the quality control system of the early secretory pathway. It was previously thought that quality control system is restricted to the endoplasmic reticulum (ER). Here, we have examined the retention mechanisms of eight V(2) vasopressin receptor mutants. We show that mutants L62P, DeltaL62-R64 and S167L are trapped exclusively in the ER. In contrast, mutants R143P, Y205C, InsQ292, V226E and R337X reach the ER/Golgi intermediate compartment (ERGIC) and are rerouted to the ER. The ability of the mutant receptors to reach the ERGIC is independent of their expression levels. Instead, it is determined by their folding state. Mutant receptors in the ERGIC may be sorted into retrograde transport vesicles by an interaction of an RXR motif in the third intracellular loop with the coatomer complex I. Our data show that disease-causing mutants of a particular membrane protein may be retained in different compartments of the early secretory pathway and that the folding states of the proteins determine their retention mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522100     DOI: 10.1111/j.1600-0854.2004.00239.x

Source DB:  PubMed          Journal:  Traffic        ISSN: 1398-9219            Impact factor:   6.215


  28 in total

Review 1.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

2.  Phosphorylation-dependent C-terminal binding of 14-3-3 proteins promotes cell surface expression of HIV co-receptor GPR15.

Authors:  Yukari Okamoto; Sojin Shikano
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

3.  Assembly-dependent surface targeting of the heterodimeric GABAB Receptor is controlled by COPI but not 14-3-3.

Authors:  Carsten Brock; Laure Boudier; Damien Maurel; Jaroslav Blahos; Jean-Philippe Pin
Journal:  Mol Biol Cell       Date:  2005-09-21       Impact factor: 4.138

Review 4.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

5.  Misfolded proteins traffic from the endoplasmic reticulum (ER) due to ER export signals.

Authors:  Margaret M Kincaid; Antony A Cooper
Journal:  Mol Biol Cell       Date:  2006-11-15       Impact factor: 4.138

6.  Heat shock response relieves ER stress.

Authors:  Yu Liu; Amy Chang
Journal:  EMBO J       Date:  2008-03-06       Impact factor: 11.598

Review 7.  Regulation of traffic and organelle architecture of the ER-Golgi interface by signal transduction.

Authors:  Kerstin D Tillmann; Valentina Millarte; Hesso Farhan
Journal:  Histochem Cell Biol       Date:  2013-07-03       Impact factor: 4.304

Review 8.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 9.  Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Authors:  P Michael Conn; Alfredo Ulloa-Aguirre
Journal:  Trends Endocrinol Metab       Date:  2009-12-11       Impact factor: 12.015

Review 10.  Hide and run. Arginine-based endoplasmic-reticulum-sorting motifs in the assembly of heteromultimeric membrane proteins.

Authors:  Kai Michelsen; Hebao Yuan; Blanche Schwappach
Journal:  EMBO Rep       Date:  2005-08       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.